Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The study showcases the company's innovative approach to targeted protein degradation, highlighting the potential of its Targeted Glues technology.
Author's summary: Amphista Therapeutics publishes novel cancer target degradation mechanism.
More News
- Women's Match Report: Torquay United 0 Exeter City 6 | Exeter City F.C.
- Canada’s Lululemon Partners With National Football League
- Announcements: week of Oct. 27, 2025 - The Rider Newspaper
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Novartis to Acquire Avidity for $12B, Bolstering Neuroscience Pipeline
- Novartis Agrees to Acquire Avidity Biosciences
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Confronting deepfakes - Opinion News | The Financial Express
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Elon Musk could step down if Tesla pay plan is rejected